| P50 | author | David Cunningham | Q38803238 |
| | Laila Ritsma | Q42801333 |
| | Malin Sund | Q44140722 |
| | Andrew Wotherspoon | Q69032669 |
| P2093 | author name string | Anthoula Lazaris | |
| | Yu Shi | |
| | Andrew R Reynolds | |
| | Clare Peckitt | |
| | Zu-Hua Gao | |
| | Xianming Tan | |
| | Peter B Vermeulen | |
| | Patrycja Gazinska | |
| | Gina Brown | |
| | Frances Daley | |
| | Gert Van den Eynden | |
| | Ayat Salman | |
| | Eve Simoneau | |
| | Peter Metrakos | |
| | Tracy J Berg | |
| | Sophia Frentzas | |
| | Victoria L Bridgeman | |
| | Luc Dirix | |
| | Steven Van Laere | |
| | Eleftherios Kostaras | |
| | Shane Foo | |
| | Evelyne Loyer | |
| | Alla Khashper | |
| | Hanna Nystrom | |
| | Jacco Van Rheenen | |
| | Mark Nathan | |
| | Zak Eltahir | |
| P2860 | cites work | VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex | Q24293027 |
| | Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 |
| | Statistical methods for assessing agreement between two methods of clinical measurement | Q26778461 |
| | The vascular basement membrane as "soil" in brain metastasis | Q27348725 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 |
| | Tumor angiogenesis | Q29614938 |
| | Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Q29622818 |
| | Selection for hepatic resection of colorectal liver metastases: expert consensus statement | Q30415026 |
| | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | Q30543788 |
| | Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. | Q33226862 |
| | Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis | Q33622791 |
| | Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions | Q33770680 |
| | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer | Q34022546 |
| | Lack of angiogenesis in experimental brain metastases | Q34048921 |
| | Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases | Q34070129 |
| | Serpins promote cancer cell survival and vascular co-option in brain metastasis | Q34407528 |
| | Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial | Q34656044 |
| | Biomarkers of response and resistance to antiangiogenic therapy | Q34673567 |
| | Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption | Q34997337 |
| | Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver | Q35418987 |
| | Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. | Q35570450 |
| | Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. | Q35966757 |
| | Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors | Q35967197 |
| | Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer | Q36024588 |
| | Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases | Q36294948 |
| | Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases | Q36457189 |
| | Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells. | Q36685121 |
| | EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance | Q37153834 |
| | Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment? | Q37236229 |
| | Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma | Q37245796 |
| | Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress | Q37259527 |
| | American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). | Q37768426 |
| | Nucleating actin for invasion | Q37843451 |
| | CT findings of response and recurrence, independent of change in tumor size, in colorectal liver metastasis treated with bevacizumab. | Q37959842 |
| | Infarct-like necrosis: a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy | Q37981011 |
| | The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications | Q38093823 |
| | Correlation between liver metastasis of the colocalization of actin-related protein 2 and 3 complex and WAVE2 in colorectal carcinoma | Q38302377 |
| | Antiangiogenic therapy in oncology: current status and future directions | Q38725587 |
| | Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia | Q38797959 |
| | Mechanism of tumour vascularization in experimental lung metastases | Q38947459 |
| | Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option | Q40511146 |
| | Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis | Q40755079 |
| | Angiogenesis in primary lung cancer and lung secondaries | Q41372713 |
| | Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice | Q42041511 |
| | The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model | Q44038918 |
| | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. | Q44486167 |
| | RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer | Q44963911 |
| | Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases | Q46931957 |
| | The histological growth pattern of colorectal cancer liver metastases has prognostic value | Q47942254 |
| | Involvement of Arp2/3 complex in the process of colorectal carcinogenesis | Q48022663 |
| | Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. | Q51670153 |
| | A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection | Q57088820 |
| | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 |
| | Angiogenesis is redundant for tumour growth in lymph node metastases | Q63634044 |
| | Perilesional enhancement of hepatic metastases: correlation between MR imaging and histopathologic findings-initial observations | Q73634746 |
| | Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast Cancer Progression Working Party | Q73837102 |
| | Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia | Q74845840 |
| | RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br | Q85077949 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 1294-1302 | |
| P577 | publication date | 2016-10-17 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases | |
| P478 | volume | 22 | |